Displaying 41 - 60 of 319
FTC Announces Tentative Agenda for July 20 Open Commission Meeting
FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market
FTC Further Expands Inquiry Into Prescription Drug Middlemen Industry Practices
FTC, DOJ Issue Summary on Joint Pharmaceutical Merger Analysis Workshop
FTC Deepens Inquiry into Prescription Drug Middlemen
Amgen Inc. and Horizon Therapeutics plc, FTC v.
Sage Chemical, Inc. et al. v. Supernus Pharmaceuticals, Inc. et al.
Endo Pharmaceuticals Inc./Amneal Pharmaceuticals, Inc.
The FTC is suing Endo Pharmaceuticals, Inc., Endo International plc, Impax Laboratories, LLC, and Impax’s owner, Amneal Pharmaceuticals, Inc., alleging that a 2017 agreement between Endo and Impax violated the antitrust laws by eliminating competition in the market for oxymorphone ER. The complaint charges the defendants with violating Sections 1 and 2 of the Sherman Act, which constitutes unfair methods of competition in violation of Section 5 of the FTC Act. Specifically, Endo, Impax, and Amneal are charged with entering into an illegal agreement in restraint of trade, and Amneal is charged with monopolization of the oxymorphone ER market. The complaint was filed in the U.S. District Court for the District of Columbia on Jan. 25, 2021.
FTC Asks Federal Court to Hold ‘Pharma Bro’ Martin Shkreli in Contempt
Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC
FTC to Ramp Up Enforcement Against Any Illegal Rebate Schemes, Bribes to Prescription Drug Middleman That Block Cheaper Drugs
Oral Remarks of Christine S. Wilson at Open Commission Meeting on June 16, 2022
Displaying 41 - 60 of 319